← Back to Clinical Trials
Recruiting NCT06753396

NCT06753396 The Effect of Injectable Platelet-Rich Fibrin in Peri-implant Soft Tissue

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06753396
Status Recruiting
Phase
Sponsor Kutahya Health Sciences University
Condition Peri-Implant Tissues
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2022-12-15
Primary Completion 2025-12-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Platelet rich fibrin

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2022-12-15 with a primary completion date of 2025-12-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

An inadequate amount of peri-implant soft tissue results in more plaque accumulation around the implants, peri-implant mucositis, marginal bone loss, mucosal recession, and/or attachment loss. In the literature, there are studies evaluating the application of injectable platelet-rich fibrin to the gingiva and oral mucosa around teeth, but injectable platelet-rich fibrin application around implants has not been encountered. This study aimed to evaluate the effect of subgingival and submucosal application of injectable platelet-rich fibrin on peri-implant soft tissue phenotype in patients with inadequate peri-implant soft tissue phenotype.The study will include 80 systemically healthy and non-smoking patients/implants older than 18 years of age with insufficient peri-implant keratinized mucosa width and mucosal thickness who applied to Kütahya University of Health Sciences, Faculty of Dentistry, Department of Periodontology. There are two study groups according to peri-implant mucosa phenotype: Thin phenotype and thick phenotype. All patients will undergo the same procedure of injectable platelet-rich fibrin application

Eligibility Criteria

Inclusion Criteria: 1. be over 18 years old 2. The patient does not have any systemic disease 3. Patients who do not smoke or who smoke less than 10 cigarettes 4. Peri-implant keratinized mucosa width less than 2 mm 5. Peri-implant mucosal thickness less than 2 mm Exclusion Criteria: 1. Being out of the defined age group 2. Any systematic contraindication for periodontal surgery 3. Patients who smoke more than 10 cigarettes per day 4. Patients with adequate peri-implant keratinized mucosa width and mucosal thickness 5. Pregnancy 6. Patients taking medication that suppresses the immune system or impairs healing 7. Patients taking medication that impairs the bleeding condition

Contact & Investigator

Central Contact

Berceste Güler Ayyıldız

✉ berceste.guler@ksbu.edu.tr

📞 +05059359207

Principal Investigator

Berceste Güler Ayyıldız, Assoc. Prof. Dr

STUDY DIRECTOR

Kütahya Health Sciences University

Frequently Asked Questions

Who can join the NCT06753396 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Peri-Implant Tissues. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06753396 currently recruiting?

Yes, NCT06753396 is actively recruiting participants. Contact the research team at berceste.guler@ksbu.edu.tr for enrollment information.

Where is the NCT06753396 trial being conducted?

This trial is being conducted at Kütahya, Turkey (Türkiye).

Who is sponsoring the NCT06753396 clinical trial?

NCT06753396 is sponsored by Kutahya Health Sciences University. The principal investigator is Berceste Güler Ayyıldız, Assoc. Prof. Dr at Kütahya Health Sciences University. The trial plans to enroll 80 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology